These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22571758)

  • 21. Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53.
    Wang Q; Dai HP; Liu DD; Xie JD; Yao H; Ding ZX; Tao TT; Chen SN; Zhang R
    Leuk Res Rep; 2020; 14():100229. PubMed ID: 33194542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
    Schwaab J; Ernst T; Erben P; Rinke J; Schnittger S; Ströbel P; Metzgeroth G; Mossner M; Haferlach T; Cross NC; Hochhaus A; Hofmann WK; Reiter A
    Ann Hematol; 2012 Nov; 91(11):1713-20. PubMed ID: 23010802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Genomic aberrations in myelodysplastic syndromes and related disorders].
    Makishima H
    Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.
    Jekarl DW; Han SB; Kim M; Lim J; Oh EJ; Kim Y; Kim HJ; Min WS; Han K
    Korean J Hematol; 2010 Mar; 45(1):46-50. PubMed ID: 21120162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.
    Li Y; Beck RC; Moore EM
    Am J Clin Pathol; 2021 Sep; 156(4):634-643. PubMed ID: 33877292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 29. Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
    Jain T; Ware AD; Dalton WB; Pasca S; Tsai HL; Gocke CD; Gondek LP; Xian RR; Borowitz MJ; Levis MJ
    Leuk Res; 2023 Aug; 131():107345. PubMed ID: 37354804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.
    Nguyen-Khac F; Lesty C; Eclache V; Couronné L; Kosmider O; Andrieux J; Collonge-Rame MA; Penther D; Lafage M; Bilhou-Nabera C; Chapiro E; Mozziconacci MJ; Mugneret F; Gachard N; Nadal N; Lippert E; Struski S; Dastugue N; Cabrol C; Bernard OA;
    Genes Chromosomes Cancer; 2010 Oct; 49(10):919-27. PubMed ID: 20629097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
    Beer PA; Delhommeau F; LeCouédic JP; Dawson MA; Chen E; Bareford D; Kusec R; McMullin MF; Harrison CN; Vannucchi AM; Vainchenker W; Green AR
    Blood; 2010 Apr; 115(14):2891-900. PubMed ID: 20008300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.
    Larsson N; Lilljebjörn H; Lassen C; Johansson B; Fioretos T
    Eur J Haematol; 2012 Feb; 88(2):136-43. PubMed ID: 21933280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
    Migas A; Savva N; Mishkova O; Aleinikova OV
    Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML.
    Behnert A; Lee AG; Young EP; Breese MR; Leung SG; Behroozfard I; Maruffi M; Sweet-Cordero EA; Dvorak CC; Chu J; Stieglitz E
    J Pediatr Hematol Oncol; 2021 Aug; 43(6):e808-e811. PubMed ID: 32815876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
    Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
    Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
    Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
    Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
    Zoi K; Cross NC
    Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.
    Fu Y; Schroeder T; Zabelina T; Badbaran A; Bacher U; Kobbe G; Ayuk F; Wolschke C; Schnittger S; Kohlmann A; Haferlach T; Kröger N
    Eur J Haematol; 2014 Mar; 92(3):189-94. PubMed ID: 24164563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
    Sugimoto Y; Muramatsu H; Makishima H; Prince C; Jankowska AM; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.